topic

1447 STUB1 regulates IFNGR1 expression and IFNG sensitivity in human tumor cell lines
Bonny Alvarenga, Kayla Walzer, Yihong Guan, Ritu Kushwaha, Connor Rosen

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1610; DOI: 10.1136/jitc-2023-SITC2023.1447
1448 Expression analysis of miRNA-4716–3p and its target AKT2 gene in blood cancer patients
Jairus Nandwa, Azhar Mehmood, Ishrat Mahjabeen, Mahmood Kayani

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1611; DOI: 10.1136/jitc-2023-SITC2023.1448
1449 NCG-M is a triple immunodeficient mouse with increased reconstitution of human myeloid cell populations for use in immunotherapy preclinical research
Steven Bronson, Jenny Rowe, Christoph Eberle, Robert Mihalek, Ann Fiore, Stephen Festin

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1612; DOI: 10.1136/jitc-2023-SITC2023.1449
1450 Dissecting the tumor associated astrocytes using the BacTRAP animal model of SHH-medulloblastoma and their potential value as therapeutic targets
Terence Duarte, João Borduqui, Gustavo Teixeira, Silvia Teixeira, Rui Reis

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1613; DOI: 10.1136/jitc-2023-SITC2023.1450
1451 The implantation site impacts the tumour growth kinetics and tumour immune infiltrate in EO771 and 4T1 syngeneic breast cancer models
Theoni Katopodi, Yin Xin Ho, Charlotte Bell, Lyndsey Hanson, Amy Cantrell, Emily Wright, Nick Moore, Stewart Brown, Lorraine Mooney, Jane Kendrew

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1614; DOI: 10.1136/jitc-2023-SITC2023.1451
1179 Abstract withdrawn
Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1299; DOI: 10.1136/jitc-2023-SITC2023.1179
1180 Maximizing NK cell immunotherapy in prostate cancer via TriKEs
Shee Kwan Phung, Nicholas Zorko, Madison Shackelford, Asha Bozicevich, Laura Bendzick, Carly Selleck, Yvette Soignier, Trygve Nelson, Joshua Walker, Peter Hinderlie, Philippa R Kennedy, Jeffrey S Miller, Martin Felices

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1300-A1301; DOI: 10.1136/jitc-2023-SITC2023.1180
1181 GEN1042-mIgG2a, an Fc-inert mouse-human chimeric variant of GEN1042 (DuoBody^®-CD40x4–1BB), exhibits in vivo antitumor activity and peripheral immune modulation
Karsten Pilones, Angelica Sette, Kristina Nuermberger, Monique Luijten, Maren Köhne, Jasja Wolthoorn, Alexander Muik, Sina Fellermeier-Kopf, Tahamtan Ahmadi, Oezlem Tuereci, Ugur Sahin, Maria Jure-Kunkel, Homer Adams

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1302; DOI: 10.1136/jitc-2023-SITC2023.1181
1182 Bispecific GPRC5D antibodies with potent cell-killing activity against multiple myeloma
Hayley Roth, Ileine Sanchez, Breanna Tyrell, Anna Lobley, Trevor Barnes, Alyssa Cunningham, Nnenna Nwogu, Kyle Doolan, Benjamin Doranz, Joseph Rucker, Ross Chambers

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1303; DOI: 10.1136/jitc-2023-SITC2023.1182
1183 Development of CTIM-76, a highly specific Claudin 6 bispecific antibody
Joseph Rucker, Ileine Sanchez, Kyle Doolan, Breanna Tyrell, Anna Lobley, Nicholas Molino, Kristin Shema, Kyle Guldner, Hayley Roth, Alyssa Cunningham, Kate Slovik, Eric Butz, Stanley Roberts, Kelly Byrnes-Blake, Riley Payne, Ed Calamai, Ross Chambers

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1304; DOI: 10.1136/jitc-2023-SITC2023.1183

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages